Inducement Plan[ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...][More Releases From This Source]## Explore[Health Care & Hospitals][Medical Pharmaceuticals][Conference Call Announcements][News Releases in Similar Topics]---- -- ADC Therapeutics to Participate in March Investor Conferences [Accessibility Statement] Skip NavigationLAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYS ...

LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into an amendment to its royalty purchase agreement with entities managed by HealthCare Royalty. ® Based on confidence in the long-term outlook for ZYNLONTA, ADC Therapeutics negotiated mutually beneficial updated terms with HealthCare Royalty, offering greater strategic flexibility to the Comp ...

Core Insights - ADC Therapeutics reported preliminary unaudited net product revenue of approximately $22 million for Q4 2025 and $73 million for the full year 2025, showing growth from $69.3 million in 2024 [1][3] - The company ended 2025 with cash and cash equivalents of approximately $261 million, providing a cash runway expected to last at least until 2028 [1][3] - Anticipated near-term catalysts include complete enrollment in the LOTIS-7 trial in the first half of 2026 and topline data from the LOTIS-5 Phase 3 trial in Q2 2026 [1][5] Financial Performance - ZYNLONTA net product revenue for 2025 is expected to be approximately $73 million, an increase from $69.3 million in 2024 [3] - Q4 2025 net product revenue is projected to be around $22 million, compared to $16.4 million in Q4 2024, reflecting variability in customer ordering [3] - The underlying demand for ZYNLONTA in the current 3L/3L+ DLBCL indication remained stable year-over-year [3] Clinical Developments - Updated data from the LOTIS-7 trial showed an 89.8% best overall response rate and a 77.6% complete response rate among 49 efficacy evaluable patients [4] - Enrollment in the LOTIS-7 trial is ongoing, with complete enrollment of approximately 100 patients expected in the first half of 2026 [4] - LOTIS-5 topline results are anticipated in Q2 2026, with full results expected by the end of 2026 [5] Regulatory and Strategic Outlook - Assuming positive results from ongoing trials, the company anticipates potential compendia inclusion for LOTIS-5 and LOTIS-7 in the first half of 2027, followed by regulatory approvals [2][5] - Investigator-initiated trials of ZYNLONTA in indolent lymphomas are ongoing, with promising initial data expected to be published by the end of 2026 [6] - The company has completed IND-enabling activities for a PSMA-targeting ADC and is exploring partnership opportunities [7][8]

Core Viewpoint - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will present at the J.P. Morgan Healthcare Conference on January 15, 2026 [1] Company Overview - ADC Therapeutics is focused on transforming treatment for patients through its portfolio, which includes ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC [3] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, emphasizing innovation in ADC development from clinical to manufacturing and commercialization [5] Product Development - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4] - The company is also developing a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker [4]

Core Viewpoint - ADC Therapeutics SA has granted options to purchase 6,000 common shares to a new employee as an inducement for employment, aiming to motivate and reward high performance [1][2]. Group 1: Grant Details - The grant was approved by the Compensation Committee under the Company's Inducement Plan to encourage significant contributions to the Company's success [2]. - The options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the next three years, fully vesting by the fourth anniversary [3]. Group 2: Company Overview - ADC Therapeutics is a leader in antibody drug conjugates (ADCs), with a focus on transforming treatment for patients through its portfolio, including ZYNLONTA [4]. - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [5]. - The company is also developing a next-generation PSMA-targeting ADC with a differentiated payload and novel linker [5]. Group 3: Company Operations - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, focusing on innovation in ADC development from clinical to commercialization [6].

Core Viewpoint - ADC Therapeutics is under investigation for potential securities fraud and unlawful business practices following a press release regarding clinical trial data that may have misrepresented adverse events [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics, focusing on whether the company and its officers engaged in securities fraud [1]. - The investigation is prompted by concerns over the company's recent disclosures and the implications for investors [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [2]. - The press release, while positive, noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [2]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial data, ADC's stock price fell by $0.65 per share, representing a 14.13% decline, closing at $3.95 per share on December 3, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by ADC Therapeutics and its officers or directors, following a significant stock price drop after the release of clinical trial data [1][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of ADC Therapeutics and is urging them to contact the firm regarding the investigation [1]. - The investigation focuses on whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - The press release highlighted positive aspects of the data but also noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [3]. Group 3: Stock Price Reaction - Following the announcement of the clinical trial data, ADC Therapeutics' stock price fell by $0.65 per share, representing a 14.13% decrease, closing at $3.95 per share on December 3, 2025 [4].

Core Insights - ADC Therapeutics (NYSE:ADCT) is highlighted as a promising investment opportunity, particularly in the context of its lymphoma treatment developments [1][2] - Recent positive interim Phase Ib data from the LOTIS-7 trial has led to reaffirmed buy ratings from analysts, with price targets set at $10.00 by Guggenheim and $5.00 by RBC Capital [1][2] Trial Results - The LOTIS-7 trial demonstrated an overall response rate of 89.8% and a complete response rate of 77.6% among 49 efficacy-evaluable patients, indicating strong efficacy for ZYNLONTA in treating relapsed or refractory diffuse large B-cell lymphoma [3] - The trial results support the potential of ZYNLONTA and glofitamab as leading bispecific antibody-based combinations for patients with 2L+ DLBCL [3] Regulatory Approvals - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission as a treatment option for relapsed or refractory diffuse large B-cell lymphoma, enhancing its market position [5][6] Company Overview - ADC Therapeutics is a commercial-stage biotech company focused on developing targeted cancer therapies using Antibody-Drug Conjugates (ADCs) and proprietary Pyrrolobenzodiazepine (PBD) technology [6]

Group 1: Snowflake Inc - Snowflake Inc reported third-quarter revenue of $1.21 billion, exceeding analyst estimates of $1.18 billion [1] - The company achieved adjusted earnings of 35 cents per share, surpassing analyst expectations of 31 cents per share [1] - In pre-market trading, Snowflake shares fell 8.6% to $241.85 following the earnings report [2] Group 2: Other Companies - Net Lease Office Properties saw a decline of 14.7%, with shares dropping to $25.19 in pre-market trading [4] - Symbotic Inc shares fell 10.5% to $65.50 after announcing a 10 million share offering [4] - Capricor Therapeutics Inc experienced an 8.4% dip to $27.45 after a significant increase of 371% the previous day [4] - ADC Therapeutics SA shares declined 8.1% to $3.63 following updated trial data [4] - Koninklijke Philips NV shares fell 6.8% to $26.11 in pre-market trading [4] - Omeros Corp declined 4.2% to $10.18, while Methanex Corp fell 3.8% to $35.95 [4]

Group 1: Snowflake Inc (NYSE:SNOW) - Snowflake reported third-quarter revenue of $1.21 billion, exceeding analyst estimates of $1.18 billion [1] - The company achieved adjusted earnings of 35 cents per share, surpassing analyst expectations of 31 cents per share [1] - In pre-market trading, Snowflake shares fell 8.6% to $241.85 [2] Group 2: Other Companies - Net Lease Office Properties (NYSE:NLOP) shares decreased by 14.7% to $25.19 in pre-market trading [4] - Symbotic Inc (NASDAQ:SYM) shares dropped 10.5% to $65.50 following a 10 million share offering announcement [4] - Capricor Therapeutics Inc (NASDAQ:CAPR) shares fell 8.4% to $27.45 after a significant increase of 371% the previous day [4] - ADC Therapeutics SA (NYSE:ADCT) shares declined 8.1% to $3.63 after reporting updated data from its LOTIS-7 trial [4] - Koninklijke Philips NV (NYSE:PHG) shares decreased by 6.8% to $26.11 in pre-market trading [4] - Omeros Corp (NASDAQ:OMER) shares fell 4.2% to $10.18 [4] - Methanex Corp (NASDAQ:MEOH) shares dropped 3.8% to $35.95 [4]